Gene · 4070
Papers3,230
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
901 to 920 of 3,230
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Self-Renewal Inhibition in Breast Cancer Stem Cells: Moonlight Role of PEDF in Breast Cancer. | Cancers (Basel) | 2023 | 38001682 | PubTator, text mining | PubMed |
| Unlocking New Horizons in Small-Cell Lung Cancer Treatment: The Onset of Antibody-Drug Conjugates. | Cancers (Basel) | 2023 | 38001628 | PubTator, text mining | PubMed |
| Colorectal Liver Metastasis: Can Cytokines Make the Difference? | Cancers (Basel) | 2023 | 38001618 | PubTator, text mining | PubMed |
| Genitourinary cancers updates: highlights from ASCO 2023. | J Hematol Oncol | 2023 | 37990343 | PubTator, text mining | PubMed |
| Trends in the Development of Antibody-Drug Conjugates for Cancer Therapy. | Antibodies (Basel) | 2023 | 37987250 | PubTator, text mining | PubMed |
| Assessment of PD-L1, TROP2, and nectin-4 expression in penile squamous cell carcinoma. | Hum Pathol | 2023 | 37977513 | PubTator, text mining | PubMed |
| Avelumab first-line maintenance treatment for advanced urothelial carcinoma: review of evidence to guide clinical practice. | ESMO Open | 2023 | 37976999 | PubTator, text mining | PubMed |
| Treatment of endocrine resistant metastatic breast cancer in the era of antibody drug conjugates. | Ann Transl Med | 2023 | 37970594 | PubTator, text mining | PubMed |
| Dual-inhibitory domain iCARs improve the efficiency of the AND-NOT gate CAR T strategy. | Proc Natl Acad Sci U S A | 2023 | 37963244 | PubTator, text mining | PubMed |
| The current status and future of ADC therapy for small cell Lung Cancer: a promising approach. | J Transl Med | 2023 | 37957693 | PubTator, text mining | PubMed |
| Safety evaluation of Datopotamab deruxtecan for triple-negative breast cancer: a meta-analysis. | Cancer Treat Res Commun | 2023 | 37956525 | PubTator, text mining | PubMed |
| Decoding TROP2 in breast cancer: significance, clinical implications, and therapeutic advancements. | Front Oncol | 2023 | 37954074 | PubTator, text mining | PubMed |
| PCMT1 knockdown attenuates malignant properties by globally regulating transcriptome profiles in triple-negative breast cancer cells. | PeerJ | 2023 | 37953789 | PubTator, text mining | PubMed |
| TJP3 promotes T cell immunity escape and chemoresistance in breast cancer: a comprehensive analysis of anoikis-based prognosis prediction and drug sensitivity stratification. | Aging (Albany NY) | 2023 | 37950731 | PubTator, text mining | PubMed |
| Circulating tumor biomarkers in early-stage breast cancer: characteristics, detection, and clinical developments. | Front Oncol | 2023 | 37941557 | PubTator, text mining | PubMed |
| Hepatitis C virus infects and perturbs liver stem cells. | mBio | 2023 | 37938000 | PubTator, text mining | PubMed |
Real-world effectiveness and safety of RC48-ADC alone or in combination with PD-1 inhibitors for patients with locally advanced or metastatic urothelial carcinoma: A multicenter, retrospective clinical study. | Cancer Med | 2023 | 37935113 | PubTator, text mining | PubMed |
| TROP2-directed nanobody-drug conjugate elicited potent antitumor effect in pancreatic cancer. | J Nanobiotechnology | 2023 | 37932752 | PubTator, text mining | PubMed |
| Drug repurposing a compelling cancer strategy with bottomless opportunities: Recent advancements in computational methods and molecular mechanisms. | Indian J Pharmacol | 2023 | 37929411 | PubTator, text mining | PubMed |
| Successful Trastuzumab-Deruxtecan Rechallenge After Interstitial Lung Disease: A Case Report. | J Breast Cancer | 2023 | 37926069 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4070/papers?page=46